PCO-371

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H32F3N5O6S
Molecular Weight	635.654
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(=CC(C)=C1CCS(=O)(=O)N2CCC3(CC2)N=C(NC3=O)C4=CC=C(OC(F)(F)F)C=C4)N5C(=O)NC(=O)C5(C)C

InChI

InChIKey=LDZJFVOUPUFOHX-UHFFFAOYSA-N

InChI=1S/C29H32F3N5O6S/c1-17-15-20(37-26(40)34-24(38)27(37,3)4)16-18(2)22(17)9-14-44(41,42)36-12-10-28(11-13-36)25(39)33-23(35-28)19-5-7-21(8-6-19)43-29(30,31)32/h5-8,15-16H,9-14H2,1-4H3,(H,33,35,39)(H,34,38,40)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27857062 | https://clinicaltrials.gov/ct2/show/NCT02475616 | https://adisinsight.springer.com/drugs/800042727

Chugai Pharmaceutical is developing a parathyroid 1 receptor agonist called as PCO371. It is known that parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor. PCO371 can provide a new treatment option for PTH-related disorders, including hypoparathyroidism. This drug participated in phase I clinical trial in healthy volunteers. However, Chugai Pharmaceutical has terminated this study. No recent reports of the development of PCO371are available.

Originator

Approval Year

PubMed

Title	Date	PubMed
Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.	2016 Nov 18	27857062

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

Name

Type

Language

PCO-371

Common Name

English

PC-0371

Common Name

English

PCO371

Code

English

2,4-IMIDAZOLIDINEDIONE, 1-(3,5-DIMETHYL-4-(2-((4-OXO-2-(4-(TRIFLUOROMETHOXY)PHENYL)-1,3,8-TRIAZASPIRO(4.5)DEC-1-EN-8-YL)SULFONYL)ETHYL)PHENYL)-5,5-DIMETHYL-

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

455914